USC scientists have found that immature immune cells can multiply in the lab and be engineered to hunt tumors, challenging a textbook rule.
What if the best cancer drug were a factory, not a pill? That is the odd, hopeful idea behind a study just published in Cell by a team at the University of Southern California. Cancer immunotherapy has a stubborn problem. Engineered immune cells can be astonishingly powerful, yet they are hard to make in large numbers, and they often fade once they are inside the body.
Each batch is costly. Each patient needs their own. So the USC researchers asked a different question: could they start earlier in the cells' life story? They chose granulocyte-monocyte progenitors, or GMPs.
These are immature cells that normally grow up into macrophages and other defenders against infection. And here is the surprise. In the laboratory, GMPs could be grown extensively while keeping their ability to become working immune cells. The team then edited them genetically, so that they recognized specific cancer markers and boosted wider immune responses.